ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.210,55
0,26%
S&P 500
5.482,87
0,09%
Dow Jones
39.164,06
0,09%
Euro vs US Dollar
1,06866
-0,20%
Bitcoin
61.631,95
0,03%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. IN8bio Inc (INAB)

  7. IN8bio Inc (INAB) News

INAB

IN8bio (INAB)

IN8bio Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:INAB
DatumZeitQuelleÜberschriftSymbolFirma
24/06/202414h00GlobeNewswire Inc.IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceNASDAQ:INABIN8bio Inc
14/06/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INABIN8bio Inc
14/06/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INABIN8bio Inc
14/06/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INABIN8bio Inc
14/06/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INABIN8bio Inc
13/06/202422h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INABIN8bio Inc
13/06/202422h01GlobeNewswire Inc.IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100NASDAQ:INABIN8bio Inc
03/06/202414h53Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INABIN8bio Inc
03/06/202412h05GlobeNewswire Inc.IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual MeetingNASDAQ:INABIN8bio Inc
24/05/202414h00GlobeNewswire Inc.IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024NASDAQ:INABIN8bio Inc
23/05/202423h00GlobeNewswire Inc.IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual MeetingNASDAQ:INABIN8bio Inc
14/05/202416h00GlobeNewswire Inc.IN8bio Announces Upcoming Presentation at 2024 European Hematology Association CongressNASDAQ:INABIN8bio Inc
13/05/202414h00GlobeNewswire Inc.IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024NASDAQ:INABIN8bio Inc
09/05/202422h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INABIN8bio Inc
09/05/202422h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INABIN8bio Inc
09/05/202422h00GlobeNewswire Inc.IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:INABIN8bio Inc
07/05/202422h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:INABIN8bio Inc
30/04/202412h05GlobeNewswire Inc.IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed GlioblastomaNASDAQ:INABIN8bio Inc
24/04/202414h00GlobeNewswire Inc.IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingNASDAQ:INABIN8bio Inc
16/04/202422h05GlobeNewswire Inc.IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceNASDAQ:INABIN8bio Inc
09/04/202422h30GlobeNewswire Inc.IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024NASDAQ:INABIN8bio Inc
14/03/202421h00GlobeNewswire Inc.IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business HighlightsNASDAQ:INABIN8bio Inc
05/03/202422h30GlobeNewswire Inc.IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024NASDAQ:INABIN8bio Inc
26/02/202414h00Business WireIN8bio to Present at Upcoming Investor ConferencesNASDAQ:INABIN8bio Inc
14/02/202414h00GlobeNewswire Inc.IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in ImmunologyNASDAQ:INABIN8bio Inc
08/02/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INABIN8bio Inc
08/02/202422h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INABIN8bio Inc
08/02/202422h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INABIN8bio Inc
08/02/202422h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INABIN8bio Inc
08/02/202422h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INABIN8bio Inc
 Showing the most relevant articles for your search:NASDAQ:INAB

Kürzlich von Ihnen besucht

TG
CZ45VC
Commerzbank
BIT
S32522
Societe Generale Effekten
BOV
BEES3F
BANESTES ON
BOV
GFSA11
GAFISA ON
EU
PROXD
Proximus SA 1.5% until 1...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten